Overview

Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics

Status:
COMPLETED
Trial end date:
2024-10-16
Target enrollment:
Participant gender:
Summary
An open study to learn whether the study medication (vamorolone) is able to affect certain processes in the liver participating in the breakdown of drugs. This will be done by measuring the blood levels of midazolam alone and in combination with vamorolone in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Santhera Pharmaceuticals
Treatments:
Drug Evaluation
Midazolam
VBP15 compound